Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Acquired by Bridge City Capital LLC

Bridge City Capital LLC increased its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 0.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 57,892 shares of the biotechnology company’s stock after acquiring an additional 518 shares during the period. Bridge City Capital LLC owned approximately 0.06% of Corcept Therapeutics worth $2,917,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CORT. Jacobs Levy Equity Management Inc. grew its stake in shares of Corcept Therapeutics by 40.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,223,781 shares of the biotechnology company’s stock worth $56,637,000 after purchasing an additional 352,947 shares during the last quarter. Braun Stacey Associates Inc. acquired a new position in Corcept Therapeutics in the fourth quarter worth approximately $14,935,000. FMR LLC increased its holdings in shares of Corcept Therapeutics by 24.6% in the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock valued at $63,122,000 after buying an additional 269,074 shares in the last quarter. Synergy Asset Management LLC lifted its position in shares of Corcept Therapeutics by 131.3% during the 4th quarter. Synergy Asset Management LLC now owns 462,411 shares of the biotechnology company’s stock valued at $22,369,000 after acquiring an additional 262,503 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Corcept Therapeutics during the 4th quarter worth $12,084,000. 93.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $115.00 target price on shares of Corcept Therapeutics in a report on Thursday, February 27th. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.75.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, CEO Joseph K. Belanoff sold 2,924 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the completion of the sale, the chief executive officer now directly owns 3,019,411 shares of the company’s stock, valued at $183,912,324.01. The trade was a 0.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Sean Maduck sold 18,303 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $60.69, for a total transaction of $1,110,809.07. Following the transaction, the insider now owns 85,622 shares in the company, valued at approximately $5,196,399.18. This trade represents a 17.61 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 45,627 shares of company stock valued at $2,557,674. 20.50% of the stock is owned by insiders.

Corcept Therapeutics Trading Up 1.9 %

NASDAQ:CORT opened at $58.66 on Friday. The stock has a market cap of $6.19 billion, a PE ratio of 46.56 and a beta of 0.61. Corcept Therapeutics Incorporated has a fifty-two week low of $20.84 and a fifty-two week high of $75.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock’s 50-day moving average is $61.49 and its two-hundred day moving average is $53.81.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $181.89 million for the quarter, compared to analysts’ expectations of $200.12 million. As a group, equities research analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.